IBIO News - Candlesense

Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July

Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth

How does IBIO's margin expansion from these cartridge sales compare to peers in the biotech consumables space, and what implications does that have for its valuation relative to the industry? Is the record cartridge volume sustainable, and what are the risks to maintaining this growth trajectory in the coming quarters? How will the 60% YoY increase in higher‑margin cartridge sales affect IBIO's upcoming earnings guidance and EPS forecasts?

Earnings

2 days ago

iBio Announces Pricing of $50 Million Public Offering

SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the...

What are the intended uses of the $50 million proceeds and how might they affect iBio’s cash‑flow and growth trajectory? How does the pricing of the $50 million offering compare to iBio’s current market valuation and recent financing activity? What is the expected dilution effect of the pre‑funded and Series G/H warrants on existing shareholders?

Financing

2 days ago

iBio Announces Proposed Public Offering

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (t...

How large is the expected capital raise from this offering and what market conditions could affect its completion? What are the exercise prices, expiration dates, and conversion ratios of the Series G and H warrants relative to iBio's current share price? What is the potential dilution impact of the pre‑funded warrants on current shareholders?

Offering

3 days ago